Ixazomib works by inhibiting the proteasome, a complex that degrades unneeded or damaged proteins in cells. By blocking this process, ixazomib causes an accumulation of proteins within the cancer cells, leading to cellular stress and eventually cell death. This mechanism is particularly effective in multiple myeloma cells, which rely heavily on the proteasome for their survival and proliferation.
